News & Insights

Gunderson Dettmer represented client Encodia, a biotech company developing next-generation solutions for proteomics research, in its $75 million Series C financing led by Northpond Ventures and Deerfield Management.

Gunderson Dettmer partners Ryan Gunderson and Jeff Thacker hosted a discussion on the benefits and considerations of raising capital from crossover funds as part of a post- IPO Summit series of workshops.

Foresite Labs incubated company, Vignette Bio, announces its acquisition by Candid Therapeutics, an innovative biotechnology company developing T-cell engager (“TCE”) antibodies 

Pioneer in the transcatheter treatment of aortic regurgitation (AR), JenaValve Technology, announces its agreement to be acquired by Edwards Lifesciences

Developer of pioneering technologies to empower science, Element Biosciences, announces its $277 million Series D financing led by Wellington Management

Gunderson Dettmer has been recognized in China Business Law Journal’s 2024 “Deals of the Year” report for our participation in a standout transaction in the PE/VC category.

29 Gunderson Dettmer attorneys were recognized in Best Lawyers' 2025 Best Lawyers in America Guide

Best Lawyers named 25 Gunderson Dettmer attorneys to its 2024 edition of The Best Lawyers in America.